17,692 Shares in Voyager Therapeutics, Inc. (NASDAQ:VYGR) Acquired by Virtu Financial LLC

Virtu Financial LLC acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,692 shares of the company’s stock, valued at approximately $100,000.

A number of other hedge funds have also recently bought and sold shares of VYGR. Picton Mahoney Asset Management lifted its stake in shares of Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after acquiring an additional 2,444 shares during the period. Intech Investment Management LLC bought a new stake in Voyager Therapeutics during the 3rd quarter worth about $74,000. SG Americas Securities LLC lifted its position in Voyager Therapeutics by 86.7% during the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock valued at $131,000 after purchasing an additional 10,704 shares during the period. Verition Fund Management LLC bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $216,000. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock worth $223,000 after buying an additional 7,573 shares during the period. 48.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

VYGR has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, March 13th. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Finally, Canaccord Genuity Group cut their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Voyager Therapeutics has an average rating of “Buy” and an average target price of $13.97.

Voyager Therapeutics Stock Down 2.4 %

NASDAQ:VYGR opened at $3.65 on Monday. Voyager Therapeutics, Inc. has a 12-month low of $3.56 and a 12-month high of $10.66. The firm has a market capitalization of $201.51 million, a price-to-earnings ratio of 5.14 and a beta of 0.99. The stock’s 50 day moving average price is $4.51 and its two-hundred day moving average price is $5.64.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. During the same quarter last year, the company posted $1.25 EPS. Equities research analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.